CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet

The IMiDs immunomodulatory drugs are an expanding family of compounds under investigation in a broad range of diseases because they exhibit immunomodulatory and anti-tumorigenic properties. Although the molecular targets remain unidentified, the broad activity of select IMiDs immunomodulatory drugs...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 128(2008), 3 vom: 15. Sept., Seite 392-9
1. Verfasser: Xu, Weiming (VerfasserIn)
Weitere Verfasser: Celeridad, Maria, Sankar, Sabita, Webb, David R, Bennett, Brydon L
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2008
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article GATA3 Transcription Factor GATA3 protein, human Interleukin-2 Receptors, Antigen, T-Cell T-Box Domain Proteins T-box transcription factor TBX21 Tumor Necrosis Factor-alpha Thalidomide 4Z8R6ORS6L mehr... Interferon-gamma 82115-62-6 pomalidomide D2UX06XLB5
LEADER 01000naa a22002652 4500
001 NLM180325965
003 DE-627
005 20231223155303.0
007 cr uuu---uuuuu
008 231223s2008 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2008.04.009  |2 doi 
028 5 2 |a pubmed24n0601.xml 
035 |a (DE-627)NLM180325965 
035 |a (NLM)18565795 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Xu, Weiming  |e verfasserin  |4 aut 
245 1 0 |a CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet 
264 1 |c 2008 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 05.09.2008 
500 |a Date Revised 15.12.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a The IMiDs immunomodulatory drugs are an expanding family of compounds under investigation in a broad range of diseases because they exhibit immunomodulatory and anti-tumorigenic properties. Although the molecular targets remain unidentified, the broad activity of select IMiDs immunomodulatory drugs on cell signaling pathways and transcription regulation has been partly described. One characteristic of these compounds is their ability to act as a co-stimulus of TCR ligation leading to increased IL-2, TNF-alpha and IFN-gamma expression indicative of a Th1 phenotype. Because clinical evidence for this response has been observed in thalidomide and lenalidomide treated patients, we investigated the effect of CC-4047 on T cell activation and differentiation at the molecular level. We used primary human CD4(+) T cells as a model and found that CC-4047 enhances the expression of transcription factor T-bet in both naive and pre-polarized Th2 cells. This modulation leads to upregulation of Th1 markers and cytokine production. By increasing the expression of T-bet, CC-4047 promotes the differentiation of naive T-cells to Th1 as well as effectively reverting Th2 cells into Th1-like effector cells in vitro. These findings elucidate a novel mechanism of action of CC-4047 on T cell differentiation, suggesting that certain IMiDs immunomodulatory drugs may have expanded clinical application in treating both allergic diseases and certain T cell lymphomas where a predominant Th2 phenotype is displayed 
650 4 |a Journal Article 
650 7 |a GATA3 Transcription Factor  |2 NLM 
650 7 |a GATA3 protein, human  |2 NLM 
650 7 |a Interleukin-2  |2 NLM 
650 7 |a Receptors, Antigen, T-Cell  |2 NLM 
650 7 |a T-Box Domain Proteins  |2 NLM 
650 7 |a T-box transcription factor TBX21  |2 NLM 
650 7 |a Tumor Necrosis Factor-alpha  |2 NLM 
650 7 |a Thalidomide  |2 NLM 
650 7 |a 4Z8R6ORS6L  |2 NLM 
650 7 |a Interferon-gamma  |2 NLM 
650 7 |a 82115-62-6  |2 NLM 
650 7 |a pomalidomide  |2 NLM 
650 7 |a D2UX06XLB5  |2 NLM 
700 1 |a Celeridad, Maria  |e verfasserin  |4 aut 
700 1 |a Sankar, Sabita  |e verfasserin  |4 aut 
700 1 |a Webb, David R  |e verfasserin  |4 aut 
700 1 |a Bennett, Brydon L  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 128(2008), 3 vom: 15. Sept., Seite 392-9  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:128  |g year:2008  |g number:3  |g day:15  |g month:09  |g pages:392-9 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2008.04.009  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 128  |j 2008  |e 3  |b 15  |c 09  |h 392-9